Registries, codifications and cardiovascular outcomes in familial hypercholesterolaemia
Katrina L Ellis 1 , Jing Pang 1 and Gerald F Watts 1, 2 Familial hypercholesterolaemia (FH), an autosomal dominant disorder characterised by significantly elevated plasma low-density lipoprotein (LDL)-cholesterol, is associated with a substantially increased risk of premature atherosclerotic cardiovascular disease (ASCVD). The majority of patients with genetically determined FH harbour a pathogenic mutation within the LDLR gene; mutations within APOB and PCSK9 occur at lower frequencies. Since the pathophysiological consequence of each of these mutations is lifelong exposure to high LDL-cholesterol, early diagnosis and initiation of lipid-lowering therapy is crucial for delaying the onset of ASCVD. 1 Although at least 15 million people worldwide are estimated to be affected by FH, most cases in the community remain undiagnosed. The underreporting of FH is a major concern and highlights the urgent need for improved knowledge and awareness of FH in primary, secondary and tertiary care settings. The establishment of well-designed and functional FH registries, and the recent ICD-10 codification of FH, can contribute to a significant improvement in the detection and documentation of FH. [2] [3] [4] Patient registries aim to collect data on individuals with a specified condition in both a systematic and standardised manner. When applied to FH, this information can be useful for initiating cascade screening, recruiting for clinical trials, improving healthcare services, facilitating patient awareness and education, and, importantly, for identifying gaps in knowledge. Ultimately, through engagement with key stakeholders, this may lead to evidence-based improvements in healthcare planning and policy making, as well as the implementation of more effective models of patient care. Expert opinion, including those outlined by The International FH Foundation, strongly recommend the establishment of patient and family registries for clinical, research and audit purposes. 5 In the current issue of EJPC, Mundal and colleagues have carried out a registry study primarily aimed at investigating cardiovascular mortality in genetically defined FH patients from the Norway population. 6 The analysis was undertaken on 5518 FH patients using data collected between 1992 and 2013; mean patient follow-up was 9.8 years (range ¼ 0.5 to 22 years). All patients were diagnosed with heterozygous FH, except for 10 individuals who had homozygous FH. The study utilised two registries, with the first, the Unit of Cardiac and Cardiovascular Genetics FH registry, 7 linked to mortality data from the Norwegian Cause of Death Registry. This later database contains information on more than 98% of all deaths in Norway, and enabled FH mortality to be compared with that of the general population. There were 189 deaths in the FH cohort, and as expected the most common documented cause of death was cardiovascular disease (42%). Interestingly, Mundal et al. identified that the standardised mortality for out-of-hospital death was 12-fold higher in younger FH patients aged between 20 and 39 years compared with individuals of the same age from the general population. This association was particularly apparent in women, who had a 19-fold increased risk of out-of-hospital mortality, but as there were just a few deaths in this subgroup of patients further validation is required in a larger sample.
We consider the most striking finding of this investigation was that in spite of genetic confirmation of FH, an FH diagnosis was only documented on 13 death certificates (6.9%) as either the underlying or a contributory cause of death. The recent approval of a code (ICD-10) for FH is a major advance for codifying FH as a cause of cardiovascular morbidity and mortality (https://thefh foundation.org/the-icd-10-codes-for-familial-hypercho lesterolemia-are-approved). However, these ICD-10
codes have yet to be universally approved and implemented worldwide. We urge that all health professionals and patient support groups strongly advocate for the inclusion of the ICD-10 for FH, or its modification in their national coding system for diseases. This is important because this will not only help to raise awareness of FH, but will also enable appropriate development of health policy, and allow more equitable allocation of health resources that will improve care of FH.
The information on cardiovascular outcomes from this Norwegian Registry also adds to recent data from smaller cohorts of FH patients in relation to myocardial infarction (MI) and acute coronary syndromes (ACSs). [8] [9] [10] [11] [12] [13] [14] [15] [16] These data may be summarised as follows: FH is relatively common among patients with ACS; for the same level of LDL-cholesterol ACS risk is higher in people with an FH causing mutation; only 75% of FH patients with ACS are receiving high potency statins and those on therapy infrequently attain a guideline recommended LDL-cholesterol target of <1.8 mmol/l; a first MI is accelerated by 15 years compared with non-FH patients, with a 2-fold greater risk of a recurrent event within first year post-MI and death from a recurrent event occurring at mean age of 60 years, particularly in men. [8] [9] [10] [11] [12] [13] At present, the greatest reduction in FH-associated cardiovascular risk is achieved through early diagnosis, preferably in childhood, followed by the initiation of statin therapy and lifestyle modification. However, a significant proportion of patients are middle-aged at the time of diagnosis, and as such have a high cholesterol-life year burden. In these patients, the use of PCSK9 inhibitors, which lower LDL-cholesterol by approximately 60%, offers a major therapeutic advance for mitigating the life-burden of LDL-cholesterol and the associated risk of ASCVD. 17, 18 In addition to the Norwegian registry, several other international FH registries have either been established or are currently under development. This includes, but is not limited to, the Simon Broome Familial Hyperlipidaemia Register in the United Kingdom, 19 the Dutch Lipid Network in the Netherlands, 20 SAFE-HEART in Spain, 21 the US CASCADE-FH registry 22 as well those in Canada, 23 France, 24 Taiwan, Czech Republic, Wales 25 and Australasia 26 (Table 1) . [19] [20] [21] [22] [23] [24] [25] 27, 28 The Simon Broome Familial Hyperlipidaemia Register was launched in 1980, with the aim of identifying all patients with FH in the United Kingdom. 19 This registry led to the development of the Simon Broome criteria, an internationally accepted clinical criteria for diagnosing FH. Likewise, the Dutch Lipid Clinic Network, which commenced in 1994 and has more than 30,000 patients enrolled, led to the establishment the Dutch Lipid Clinic Network criteria, another widely implemented diagnostic score. SAFE-HEART is an ongoing long-term prospective cohort study carried out in genetically defined FH patients recruited from nineteen outpatient clinics in Spain. That study was designed to investigate the prognostic factors and mechanisms that contribute to the development of coronary artery disease in the FH population. 21 More recently, CASCADE-FH was established by the FH Foundation in order to address the low frequency of FH diagnosed in the United States (<10% of cases are currently identified). 22 Patients are enrolled into the registry if they have been diagnosed with FH based on either existing clinical or genetic diagnostic criteria. The British Columbia FH Registry was also reported in 2013, 23 and has since been merged with the FH Canada Registry. The FH Australasia Registry was launched in 2015, and currently contains information on approximately 800 hypercholesterolaemic patients from Australia and New Zealand. 29 The French Cohort of FH was also initiated in 2015 and has a current enrolment of over 3000 patients. 24 Moving into the future, the establishment of global and regional registries will be a key focus. However, this requires the coordination and harmonisation of multiple factors including inter-operable registry platforms, standardised methods of data collection and, importantly, agreement on the ethical frameworks. The European Atherosclerosis Society has recently launched the FH Studies Collaboration, a global initiative that aims through a consortium of major FH registries to generate large-scale and robust data on FH. 3 A collaborative initiative, 'The Ten Countries Study', aimed to address country specific questions relating to FH in the Asia-Pacific region and the southern hemisphere, and accordingly plans to pilot a regional webbased registry. 4 Asia is estimated to have the largest population density of FH in the world, and as such the development of a registry will be important for buttressing the major gaps in knowledge of FH, and for assessing whether the findings from other registries, including Norway, extend to affected patients in this highly populous region.
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